Gwendolyn A. McMillin, PhD

Professor, University of Utah School of Medicine

Education

• Doctorate Degree—Pharmacology, University of Utah
• Fellowship—Clinical Chemistry, University of Utah

Certification/Affiliations

• American Board of Clinical Chemistry (Clinical Chemistry, Toxicological Chemistry)

Research Interests

• Pharmacogenomics
• Newborn Drug Exposures
• Analytical Methods

Awards

• Past Chair Award, TDM and Toxicology Division, American Association for Clinical Chemistry, 2014
• Ellis Benson Young Investigator Award, Academy of Clinical Laboratory Physicians and Scientists, 2012
• Outstanding Speaker Award, American Association for Clinical Chemistry 2009, 2011, and 2013

Recent Publications

• Krasowski MD, McMillin GA, Melanson SEF, et al. Interpretation and utility of drug of abuse screening immunoassays: insights from laboratory drug testing proficiency surveys. Arch Pathol Lab Med. 2020;144(2):177-184.
• Wabuyele SL, McMillin GA. Quantitation of Ethyl-β-D-glucuronide in human umbilical cord tissue by liquid chromatography tandem mass spectrometry (LC-MS/MS). Methods Mol Biol. 2019;1872:223-236.
• Wu F, Jensen TL, McMillin GA. Detection of in utero cannabis exposure in umbilical cord tissue by a sensitive liquid chromatography-tandem mass spectrometry method. Methods Mol Biol. 2019;1872:211-222.
• Wu F, Melis R, McMillin GA, et al. Retrospective data analysis of the influence of age and sex on TPMT activity and its phenotype-genotype correlation. J Appl Lab Med. 2019;3(5):827-838.
• Metz TD, Silver RM, McMillin GA, et al.  Prenatal marijuana use by self-report and umbilical cord sampling in a state with legalization. Obstet Gynecol. 2019;133(1):98-104.
• Melis R, Mohamed J, Ha Y, et al. Post-mortem CYP2D6 genotyping and copy number determinations using DNA extracted from archived FTA bloodstains. J Anal Toxicol. 2019;43(5):411-414.
• Maharjan AS, McMillin GA, Patel GK, et al. The prevalence of DPYD*9A(c.85T>C) genotype and the genotype-phenotype correlation in patients with gastrointestinal malignancies treated with fluoropyrimidines: updated analysis. Clin Colorectal Cancer. 2019;18(3):e280-e286.
• Wood KE, McMillin GA, Krasowski MD. Risk-based newborn drug testing in a setting with a low prevalence of maternal drug use. Hosp Pediatr. 2019;9(8):593-600.
• Gaedigk A, Turner A, Everts RE, et al. Characterization of reference materials for genetic testing of rare CYP2D6 alleles: a GeT-RM collaborative project. J Mol Diag. 2019;21(6):1034-1052.
• Hoshitsuki K, Crews KR, Yang W, et al. Challenges in clinical implementation of CYP2D6 genotyping: choice of variants to test affects phenotype determination. Genet Med. 2020;22(1):232-233.
• Gage BF, Bass AR, Lin H, et al. Effect of low-intensity vs. standard-intensity warfarin prophylaxis on venous thromboembolism or death among patients undergoing hip or knee arthroplasty: a randomized clinical trial. JAMA. 2019;322(9):834-842.
• Wu F, Scroggin TL, Metz TD, et al. Development of a liquid chromatography-tandem mass spectrometry method for the simultaneous determination of four cannabinoids in umbilical cord tissue. J Anal Toxicol. 2018;42(1):42-48.
• Scroggin TL, McMillin GA. Quantitation of cocaine and metabolites, phencyclidine, butalbital and phenobarbital in meconium by liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2018;42(3):177-182.
• Leung EKY, Agolini E, Pei X, et al. Validation of an extensive CYP2D6 assay panel based on invader and TaqMan copy number assays. J Appl Lab Med. 2017;1(5):471-482.
• Wu F, et alMarin SJ, McMillin GA. Stability of 21 cocaine, opioid, and benzodiazepine drug analytes in meconium at three temperatures. J Anal Toxicol. 2017;41(3):196-204.
• Gage BF, Bass AR, Lin H, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty: The GIFT randomized clinical trial. JAMA. 2017;318(12):1115-1124.
• Jannetto PJ, Bratanow NC, Clark WA, et al. Executive summary: American Association of Clinical Chemistry Laboratory Medicine practice guideline – using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2017;2(4):489-526.
• McMillin GA. Pharmacogenetics of opioid use and implications for pain management – are we ready? J Appl Lab Med. 2017;2(4):481-484.